Compare Stocks: XCUR, CNTX, MDXH, and GOSS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.37 +0.5%	$0.49	$0.34 ▼ $3.62	$33.82M	1.69	1.68 million shs	744,991 shs
GOSS Gossamer Bio	$11.28 +5.1%	$13.11	$9.10 ▼ $309.60	$31.48M	2	247,085 shs	258,790 shs
MDXH MDxHealth	$0.60 -4.8%	$0.59	$0.40 ▼ $5.33	$31.18M	1.57	223,938 shs	347,712 shs
XCUR Exicure	$1.26 +2.4%	$1.44	$1.05 ▼ $9.48	$8.05M	3.63	36,998 shs	32,063 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	0.00%	+5.05%	-26.39%	-41.56%	-61.98%
GOSS Gossamer Bio	0.00%	0.00%	-13.30%	-18.32%	-95.60%
MDXH MDxHealth	0.00%	-10.59%	-15.22%	+26.63%	-84.78%
XCUR Exicure	0.00%	-12.14%	+6.96%	-55.11%	-67.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTX Context Therapeutics	$0.37 +0.5%	$0.49	$0.34 ▼ $3.62	$33.82M	1.69	1.68 million shs	744,991 shs
GOSS Gossamer Bio	$11.28 +5.1%	$13.11	$9.10 ▼ $309.60	$31.48M	2	247,085 shs	258,790 shs
MDXH MDxHealth	$0.60 -4.8%	$0.59	$0.40 ▼ $5.33	$31.18M	1.57	223,938 shs	347,712 shs
XCUR Exicure	$1.26 +2.4%	$1.44	$1.05 ▼ $9.48	$8.05M	3.63	36,998 shs	32,063 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTX Context Therapeutics	0.00%	+5.05%	-26.39%	-41.56%	-61.98%
GOSS Gossamer Bio	0.00%	0.00%	-13.30%	-18.32%	-95.60%
MDXH MDxHealth	0.00%	-10.59%	-15.22%	+26.63%	-84.78%
XCUR Exicure	0.00%	-12.14%	+6.96%	-55.11%	-67.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTX Context Therapeutics	2.70	Moderate Buy	$6.17	1,546.20% Upside
GOSS Gossamer Bio	2.22	Hold	$256.00	2,169.50% Upside
MDXH MDxHealth	2.40	Hold	$2.17	261.11% Upside
XCUR Exicure	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XCUR, CNTX, MDXH, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	MDXH MDxHealth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	XCUR Exicure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/3/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/21/2026	MDXH MDxHealth	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$4.00 ➝ $2.00
8/20/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/14/2026	MDXH MDxHealth	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$5.00 ➝ $3.00
8/6/2026	CNTX Context Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	CNTX Context Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	$0.66 per share	N/A
GOSS Gossamer Bio	$48.47M	0.68	N/A	N/A	($42.43) per share	-0.27
MDXH MDxHealth	$114.02M	0.26	N/A	N/A	($0.24) per share	-2.50
XCUR Exicure	N/A	N/A	N/A	N/A	$0.62 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTX Context Therapeutics	-$36.12M	-$0.48	N/A	N/A	N/A	N/A	-82.06%	-72.74%	11/4/2026 (Estimated)
GOSS Gossamer Bio	-$170.37M	-$56.00	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)
MDXH MDxHealth	-$33.52M	-$0.72	N/A	N/A	N/A	-33.46%	N/A	-24.25%	N/A
XCUR Exicure	-$4.95M	-$1.32	N/A	N/A	N/A	N/A	-237.91%	-61.98%	11/12/2026 (Estimated)

Latest XCUR, CNTX, MDXH, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	MDXH MDxHealth	-$0.1934	-$0.18	+$0.0134	-$0.22	$26.14 million	$27.21 million
8/14/2026	Q2 2026	XCUR Exicure	-$18.60	-$0.18	+$18.42	-$0.18	$1.64 million	N/A
8/5/2026	Q2 2026	CNTX Context Therapeutics	-$0.0921	-$0.15	-$0.0579	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTX Context Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
MDXH MDxHealth	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTX Context Therapeutics	N/A	5.81	5.81
GOSS Gossamer Bio	N/A	0.53	0.53
MDXH MDxHealth	N/A	1.15	0.98
XCUR Exicure	N/A	0.56	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTX Context Therapeutics	14.03%
GOSS Gossamer Bio	81.23%
MDXH MDxHealth	N/A
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
CNTX Context Therapeutics	4.80%
GOSS Gossamer Bio	4.15%
MDXH MDxHealth	1.70%
XCUR Exicure	52.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTX Context Therapeutics	15	91.88 million	87.47 million	Not Optionable
GOSS Gossamer Bio	162	2.93 million	2.81 million	Optionable
MDXH MDxHealth	364	49.50 million	48.66 million	Not Optionable
XCUR Exicure	50	6.55 million	3.09 million	Not Optionable

XCUR, CNTX, MDXH, and GOSS Headlines

Recent News About These Companies

Exicure Granted Extension By Nasdaq To Regain Compliance By Dec. '26

September 16, 2026 | rttnews.com

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

September 16, 2026 | finance.yahoo.com

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement

September 16, 2026 | globenewswire.com

Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics

August 3, 2026 | quiverquant.comQ

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

August 3, 2026 | globenewswire.com

Exicure Inc (NASDAQ: XCUR) - Share Price and Research

July 15, 2026 | intelligentinvestor.com.auI

Exicure Reaches Preliminary Settlement in Derivative Lawsuits

July 9, 2026 | theglobeandmail.com

Exicure Announces Board and Committee Changes

June 30, 2026 | globenewswire.com

Exicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 11, 2026 | finanznachrichten.de

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

June 10, 2026 | markets.businessinsider.com

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 10, 2026 | globenewswire.com

Exicure Regains Nasdaq Compliance After Late Quarterly Filing

June 1, 2026 | tipranks.com

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

June 1, 2026 | globenewswire.com

Exicure delays quarterly filing, trims quarterly loss

May 15, 2026 | tipranks.com

Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies

April 22, 2026 | quiverquant.comQ

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

April 22, 2026 | globenewswire.com

Exicure Inc.

April 13, 2026 | barrons.com

Exicure Strengthens Leadership With New COO and Director

April 10, 2026 | tipranks.com

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

April 2, 2026 | globenewswire.com

Exicure, Inc. Reports 2025 Financial Results and Announces Need for Additional Financing

March 25, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, CNTX, MDXH, and GOSS Company Descriptions

Context Therapeutics NASDAQ:CNTX

$0.37 +0.00 (+0.52%)

As of 04:00 PM Eastern

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Gossamer Bio NASDAQ:GOSS

$11.28 +0.55 (+5.13%)

As of 04:00 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

MDxHealth NASDAQ:MDXH

$0.60 -0.03 (-4.76%)

As of 04:00 PM Eastern

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Exicure NASDAQ:XCUR

$1.26 +0.03 (+2.44%)

As of 04:00 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XCUR, CNTX, MDXH, and GOSS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XCUR, CNTX, MDXH, and GOSS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XCUR, CNTX, MDXH, and GOSS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, CNTX, MDXH, and GOSS Company Descriptions

Context Therapeutics NASDAQ:CNTX

Gossamer Bio NASDAQ:GOSS

MDxHealth NASDAQ:MDXH

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XCUR, CNTX, MDXH, and GOSS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XCUR, CNTX, MDXH, and GOSS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XCUR, CNTX, MDXH, and GOSS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, CNTX, MDXH, and GOSS Company Descriptions

Context Therapeutics NASDAQ:CNTX

Gossamer Bio NASDAQ:GOSS

MDxHealth NASDAQ:MDXH

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools